COMP <GO>
MDLN vs SYK // EV/EBITDA & P/E VALUATION
Medline Inc. (NASDAQ) VS. Stryker Corporation (NYSE) • 15-METRIC TALLY: MDLN 3
— SYK 9
▲ EV/EBITDA & P/E VALUATION LEADER: MDLN
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
valuation
20.3x
LAST: $291.86 (-6.38%) • MKT CAP: $119.58B
valuation
23.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. SYK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | SYK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 64.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 11.60% | -3.40 | SYK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.3x | 23.6x | -3.30 | MDLN | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 3.58% | -0.50 | SYK | /fcf-yield <GO> |
| Operating Margin | 7.80% | 19.50% | -11.70 | SYK | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 12.90% | +55.10 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 11.20% | +0.30 | MDLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.07% | -1.07 | SYK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 4.46 | -1.96 | SYK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | SYK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 59.4 | -28.50 | SYK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 1.13 | -0.02 | SYK | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 34.2x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $119.58B | -$77.51B | SYK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | SYK REV | MDLN GROSS % | SYK GROSS % | MDLN FCF | SYK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $25.12B | 26.4% | 64.0% | $1.30B | $4.28B |
| FY 2024 | $25.51B | $22.59B | 27.3% | 63.9% | $1.42B | $3.49B |
| FY 2023 | $23.23B | $20.50B | — | — | $639.6M | $2.79B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
SYK // BETA 1.13